189 related articles for article (PubMed ID: 34571172)
1. Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization.
Di Sarno V; Lauro G; Musella S; Ciaglia T; Vestuto V; Sala M; Scala MC; Smaldone G; Di Matteo F; Novi S; Tecce MF; Moltedo O; Bifulco G; Campiglia P; Gomez-Monterrey IM; Snoeck R; Andrei G; Ostacolo C; Bertamino A
Eur J Med Chem; 2021 Dec; 226():113863. PubMed ID: 34571172
[TBL] [Abstract][Full Text] [Related]
2. Peptidomimetics as potent dual SARS-CoV-2 cathepsin-L and main protease inhibitors: In silico design, synthesis and pharmacological characterization.
Ciaglia T; Vestuto V; Di Sarno V; Musella S; Smaldone G; Di Matteo F; Napolitano V; Miranda MR; Pepe G; Basilicata MG; Novi S; Capolupo I; Bifulco G; Campiglia P; Gomez-Monterrey I; Snoeck R; Andrei G; Manfra M; Ostacolo C; Lauro G; Bertamino A
Eur J Med Chem; 2024 Feb; 266():116128. PubMed ID: 38232463
[TBL] [Abstract][Full Text] [Related]
3. Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2.
Kuo CJ; Chao TL; Kao HC; Tsai YM; Liu YK; Wang LH; Hsieh MC; Chang SY; Liang PH
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526482
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Identification of Naphthoquinones and Derivatives as Novel Inhibitors of Main Protease M
Santos LH; Kronenberger T; Almeida RG; Silva EB; Rocha REO; Oliveira JC; Barreto LV; Skinner D; Fajtová P; Giardini MA; Woodworth B; Bardine C; Lourenço AL; Craik CS; Poso A; Podust LM; McKerrow JH; Siqueira-Neto JL; O'Donoghue AJ; da Silva Júnior EN; Ferreira RS
J Chem Inf Model; 2022 Dec; 62(24):6553-6573. PubMed ID: 35960688
[TBL] [Abstract][Full Text] [Related]
5. Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay.
Pitsillou E; Liang J; Ververis K; Hung A; Karagiannis TC
J Mol Graph Model; 2021 May; 104():107851. PubMed ID: 33556646
[TBL] [Abstract][Full Text] [Related]
6. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
7. High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors.
Zang Y; Su M; Wang Q; Cheng X; Zhang W; Zhao Y; Chen T; Jiang Y; Shen Q; Du J; Tan Q; Wang P; Gao L; Jin Z; Zhang M; Li C; Zhu Y; Feng B; Tang B; Xie H; Wang MW; Zheng M; Pan X; Yang H; Xu Y; Wu B; Zhang L; Rao Z; Yang X; Jiang H; Xiao G; Zhao Q; Li J
Protein Cell; 2023 Jan; 14(1):17-27. PubMed ID: 36726755
[TBL] [Abstract][Full Text] [Related]
8. Diphenyl Diselenide and SARS-CoV-2:
Omage FB; Madabeni A; Tucci AR; Nogara PA; Bortoli M; Rosa ADS; Neuza Dos Santos Ferreira V; Teixeira Rocha JB; Miranda MD; Orian L
J Chem Inf Model; 2023 Apr; 63(7):2226-2239. PubMed ID: 36952618
[TBL] [Abstract][Full Text] [Related]
9. Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing.
Pathak N; Chen YT; Hsu YC; Hsu NY; Kuo CJ; Tsai HP; Kang JJ; Huang CH; Chang SY; Chang YH; Liang PH; Yang JM
ACS Nano; 2021 Jan; 15(1):857-872. PubMed ID: 33373194
[TBL] [Abstract][Full Text] [Related]
10. Discovery of juglone and its derivatives as potent SARS-CoV-2 main proteinase inhibitors.
Cui J; Jia J
Eur J Med Chem; 2021 Dec; 225():113789. PubMed ID: 34438124
[TBL] [Abstract][Full Text] [Related]
11. Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library.
Lee JY; Kuo CJ; Shin JS; Jung E; Liang PH; Jung YS
Bioorg Med Chem Lett; 2021 Jun; 42():128067. PubMed ID: 33957246
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2
Gammeltoft KA; Zhou Y; Duarte Hernandez CR; Galli A; Offersgaard A; Costa R; Pham LV; Fahnøe U; Feng S; Scheel TKH; Ramirez S; Bukh J; Gottwein JM
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0268020. PubMed ID: 34097489
[TBL] [Abstract][Full Text] [Related]
13. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp5 main protease.
Milligan JC; Zeisner TU; Papageorgiou G; Joshi D; Soudy C; Ulferts R; Wu M; Lim CT; Tan KW; Weissmann F; Canal B; Fujisawa R; Deegan T; Nagaraj H; Bineva-Todd G; Basier C; Curran JF; Howell M; Beale R; Labib K; O'Reilly N; Diffley JFX
Biochem J; 2021 Jul; 478(13):2499-2515. PubMed ID: 34198327
[TBL] [Abstract][Full Text] [Related]
14. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL
Jade D; Ayyamperumal S; Tallapaneni V; Joghee Nanjan CM; Barge S; Mohan S; Nanjan MJ
Eur J Pharmacol; 2021 Jun; 901():174082. PubMed ID: 33823185
[TBL] [Abstract][Full Text] [Related]
15. Aurasperone A Inhibits SARS CoV-2 In Vitro: An Integrated In Vitro and In Silico Study.
ElNaggar MH; Abdelwahab GM; Kutkat O; GabAllah M; Ali MA; El-Metwally MEA; Sayed AM; Abdelmohsen UR; Khalil AT
Mar Drugs; 2022 Feb; 20(3):. PubMed ID: 35323478
[TBL] [Abstract][Full Text] [Related]
16. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265
[TBL] [Abstract][Full Text] [Related]
17. Drug-Repurposing Screening Identified Tropifexor as a SARS-CoV-2 Papain-like Protease Inhibitor.
Ma C; Hu Y; Wang Y; Choza J; Wang J
ACS Infect Dis; 2022 May; 8(5):1022-1030. PubMed ID: 35404564
[TBL] [Abstract][Full Text] [Related]
18. Non-Toxic Dimeric Peptides Derived from the Bothropstoxin-I Are Potent SARS-CoV-2 and Papain-like Protease Inhibitors.
Freire MCLC; Noske GD; Bitencourt NV; Sanches PRS; Santos-Filho NA; Gawriljuk VO; de Souza EP; Nogueira VHR; de Godoy MO; Nakamura AM; Fernandes RS; Godoy AS; Juliano MA; Peres BM; Barbosa CG; Moraes CB; Freitas-Junior LHG; Cilli EM; Guido RVC; Oliva G
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443484
[TBL] [Abstract][Full Text] [Related]
19. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
[TBL] [Abstract][Full Text] [Related]
20. Combining virtual screening with cis-/trans-cleavage enzymatic assays effectively reveals broad-spectrum inhibitors that target the main proteases of SARS-CoV-2 and MERS-CoV.
Chang YJ; Le UNP; Liu JJ; Li SR; Chao ST; Lai HC; Lin YF; Hsu KC; Lu CH; Lin CW
Antiviral Res; 2023 Aug; 216():105653. PubMed ID: 37321487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
